Monday August 21, 9:56 am Eastern Time
Press Release
SOURCE: Duramed Pharmaceuticals, Inc.
Duramed Launches New Web Site
* Duramed's revised www.duramed.com adds communications channels for investors, physicians and patients, and customers * Provides increased, up-to-date Duramed information * Is the initial step in Duramed's business-to-business e-commerce development
CINCINNATI, Aug. 21 /PRNewswire/ -- Duramed Pharmaceuticals, Inc. (Nasdaq: DRMD - news) today announced the upgrade of its corporate web site, www.duramed.com . The site was developed and is administered by Global Cloud Ltd., a Cincinnati-based Internet company.
E. Thomas Arington, Duramed Chairman and Chief Executive Officer, commented, ``We are proud of Duramed's improved Internet site. We are pleased to offer an increased amount of up-to-date online information which will prove useful to everyone.''
``Duramed.com is truly a dynamic and intuitive web site,'' said Paul G. Ghiz, Global Cloud Ltd. Co-Founder and Chief Creative Officer. ``The functionality, design, and rich content will provide a satisfying and inviting experience for its visitors.''
The new site offers a variety of new features including a stock quote, a periodically-updated message from the CEO, and a women's health resource page. Furthermore, users can submit online resumes, access the Duramed product catalog, and subscribe to a press release notification list.
About Duramed Pharmaceuticals, Inc.
Duramed Pharmaceuticals develops, manufactures, and markets prescription drug products. The company's business strategy emphasizes products with attractive market opportunities and potentially limited competition due to technological barriers to entry, focusing on women's health and the hormone replacement therapy market. On March 24, 1999, the FDA approved the company's first branded product, Cenestin® (synthetic conjugated estrogens, A) Tablets, for the treatment of moderate-to-severe vasomotor symptoms associated with menopause.
Duramed's containment manufacturing facility for the production of hormones distinguishes the company from most competitors. The facility incorporates enclosed product flow and state-of-the-art environmental controls to ensure purity, stability, and tablet uniformity for Cenestin and other hormone products. While Duramed's primary focus will be solid oral dose hormones, the company's other areas of concentration-controlled release technology and oncology-continue to represent attractive market opportunities.
The company's stock is traded on Nasdaq using the symbol DRMD. Additional information about the company can be found on the World Wide Web at www.duramed.com and www.cenestin.com
Like all estrogen drug products, CENESTIN® Tablets should not be used in women with known or suspected pregnancy, breast cancer, or estrogen-dependent neoplasia, undiagnosed abnormal genital bleeding, active thrombophlebitis, or thromboembolic disorders. Estrogens have been reported to increase the risk of endometrial carcinoma in postmenopausal women with an intact uterus. The most common adverse events reported in clinical experience with CENESTIN included headache, insomnia, asthenia, nervousness, paresthesia, and depression. For additional information on CENESTIN, please see full prescribing information.
The Securities and Exchange Commission (SEC) encourages companies to disclose forward-looking information so that investors can better understand a company's future prospects and make informed investment decisions. Due to changing market conditions, product competition, the nature of product development and regulatory approval processes, the achievement of forward- looking statements contained in this press release are subject to risks and uncertainties. For further details and a discussion of these risks and uncertainties, see Duramed's SEC filings, including its annual report on Form 1O-K.
SOURCE: Duramed Pharmaceuticals, Inc. |
